Editorial
- Page Path
-
- HOME
- ARTICLE CATEGORY
- Editorial
- Editorial
- Do cirrhotic patients with a high MELD score benefit from TIPS?
- Won Hyeok Choe
- Clin Mol Hepatol. 2014;20(1):15-17. Published online March 26, 2014
-
View: 6129 Download: 45 Web of Science: 4 Crossref: 3
- Liver stiffness measurement: Is it a non-invasive substitution for HVPG?
- Soung Won Jeong
- Clin Mol Hepatol. 2013;19(4):367-369. Published online December 28, 2013
-
View: 6305 Download: 49 Crossref: 4
- Chasing after novel non-invasive markers to identify advanced fibrosis in NAFLD
- Wonseok Kang, Seung Up Kim
- Clin Mol Hepatol. 2013;19(3):255-257. Published online September 30, 2013
-
View: 5878 Download: 49 Crossref: 2
- Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis
- Goh Eun Chung, Donghee Kim
- Clin Mol Hepatol. 2013;19(2):116-119. Published online June 27, 2013
-
View: 6949 Download: 91
- Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
- Young Kul Jung, Ju Hyun Kim
- Clin Mol Hepatol. 2013;19(1):26-28. Published online March 25, 2013
-
View: 6385 Download: 47 Crossref: 4
- Elevated serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
- Byoung Kuk Jang
- Clin Mol Hepatol. 2012;18(4):357-359. Published online December 21, 2012
-
View: 7128 Download: 90 Crossref: 26
- Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients
- Woo Jin Chung
- Clin Mol Hepatol. 2012;18(3):268-271. Published online September 25, 2012
-
View: 5785 Download: 45 Crossref: 1
- Noninvasive diagnostic criteria for hepatocellular carcinoma
- Han Chu Lee
- Clin Mol Hepatol. 2012;18(2):174-177. Published online June 26, 2012
-
View: 6517 Download: 53 Crossref: 3
- The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection
- Tae Yeob Kim
- Clin Mol Hepatol. 2012;18(1):29-31. Published online March 22, 2012
-
View: 7253 Download: 34 Crossref: 4
- A tool for communication with decision-makers: limitations and utilization of studies on cost of illness
- Kun-Sei Lee
- Clin Mol Hepatol. 2011;17(4):258-260. Published online December 26, 2011
-
View: 5079 Download: 35 Crossref: 1
- Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response
- Jeong Heo
- Clin Mol Hepatol. 2011;17(3):180-182. Published online September 30, 2011
-
View: 6258 Download: 32
- Percutaneous interventional procedures in an era of liver transplantation
- Young Seok Kim
- Clin Mol Hepatol. 2011;17(2):96-98. Published online June 23, 2011
-
View: 5833 Download: 35
- Liver function tests as indicators of metabolic syndrome
- Han Chu Lee
- Clin Mol Hepatol. 2011;17(1):9-11. Published online March 21, 2011
-
View: 5542 Download: 49 Crossref: 4
- Which treatment modality should we choose for advanced hepatocellular carcinoma?
- Do Young Kim
- Clin Mol Hepatol. 2010;16(4):353-354. Published online December 31, 2010
-
View: 5912 Download: 63
- Hypoxia-inducible factor 1, hepatocellular carcinoma and angiogenesis
- Jin-Wook Kim
- Clin Mol Hepatol. 2010;16(3):278-279. Published online September 30, 2010
-
View: 5809 Download: 31 Crossref: 3
- Atezolizumab and bevacizumab for hepatocellular carcinoma: how to approach salvage therapy for non-responders?
- Naoshi Nishida
- Received May 2, 2024 Accepted May 3, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0324 [Accepted]
-
View: 328 Download: 41
- Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma
- Junlong Dai, Jimmy Che-To Lai, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip
- Received May 3, 2024 Accepted May 4, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0327 [Epub ahead of print]
-
View: 342 Download: 18
- Unlocking the Role of Liver Sinusoidal Endothelial Cells: Key Players in Liver Fibrosis
- Yasuko Iwakiri
- Received May 8, 2024 Accepted May 9, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0343 [Accepted]
-
View: 370 Download: 44
- Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure
- Hae Lim Lee, Jeong Won Jang
- Received May 9, 2024 Accepted May 13, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0346 [Accepted]
-
View: 247 Download: 21
- Unveiling Etiology-Specific Blood Biomarkers in Hepatocellular Carcinoma: A Gateway to Personalized Medicine
- Joseph C. Ahn, Ju Dong Yang
- Received May 10, 2024 Accepted May 13, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0348 [Accepted]
-
View: 368 Download: 6
- MAFLD Is A Ubiquitous Latent Cofactor in Viral- and Alcoholic-related Hepatocellular Carcinoma
- Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi
- Received May 18, 2024 Accepted May 20, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0372 [Accepted]
-
View: 422 Download: 27
- Modified quick-SOFA score: can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?
- Simone Incicco, Salvatore Piano
- Received May 30, 2024 Accepted May 31, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0409 [Accepted]
-
View: 192 Download: 7
- Ursolic acid: A promising therapeutic agent for MASLD via inhibition of SPP1-induced Th17 cell differentiation
- So Jung Kim, Jeongeun Hyun
- Received May 31, 2024 Accepted June 6, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0412 [Accepted]
-
View: 313 Download: 29
- Meeting the challenges of HCC post SVR in the Post-DAA Era: A Path Forward
- Seren M. Gedallovich, Paul Y. Kwo
- Received June 3, 2024 Accepted June 6, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0418 [Accepted]
-
View: 195 Download: 10
- Metformin and Statins and their role in reducing Hepatocellular Carcinoma Risk: Randomized trials are needed
- Paul Y. Kwo
- Received June 4, 2024 Accepted June 6, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0425 [Accepted]
-
View: 264 Download: 22
- The impact of ischemia-free liver transplantation to improve the prognosis of recipients using functionally marginal liver grafts
- Ho Joong Choi
- Received June 4, 2024 Accepted June 6, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0426 [Accepted]
-
View: 204 Download: 15
- Macrophage ATG16L1: potential candidate for MASH treatment
- Junjie Yu
- Received June 11, 2024 Accepted June 14, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0443 [Accepted]
-
View: 319 Download: 24
- Engineering HBV-specific T cells for treatment of HBV-related HCC and HBV infection: past, present and future
- Antonio Bertoletti, Anthony T Tan
- Received June 23, 2024 Accepted June 26, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0469 [Accepted]
-
View: 180 Download: 22
- Severity of microvascular invasion does matter in hepatocellular carcinoma prognosis
- Abdelrahman M Attia, Hasmik Adetyan, Ju Dong Yang
- Received June 25, 2024 Accepted June 29, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0482 [Accepted]
-
View: 249 Download: 15
- Class II Transactivator Restricts Viral Replication, Extending its Effect to HBV
- Cho-Rong Lee, Sung-Gyoo Park
- Received June 20, 2024 Accepted July 3, 2024
-
DOI: https://doi.org/10.3350/cmh.2024.0465 [Accepted]
-
View: 173 Download: 31
-
Clinical and
Molecular
HepatologyPrint ISSN: 2287-2728
Online ISSN: 2287-285X
-
-
- Immunopathogenesis of liver fibrosis in steatotic liver disease
- Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
- Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease
- The role of the hepatic autonomic nervous system
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
- Systemic therapy in advanced hepatocellular carcinoma
- Epidemiology and updated management for autoimmune liver disease
- Microbiome and metabolomics in alcoholic liver disease
- Personalized medicine in nonalcoholic fatty liver disease
- Acute on chronic liver failure in cirrhosis
- Current status and outcome of liver transplantation in South Korea
- History and future of hepatitis B virus control in South Korea
- Hepatocellular carcinoma statistics in South Korea
Impact Factor14.0First decision
09 Days
Publication after acceptance
03 Days
*Last 12 months
- MOST VIEWED (Last 6 months)
- MOST CITED (2022-2024)
|
|||||||
